NCT06054178View on ClinicalTrials.gov

Identification of Nerves Using Fluorescein Sodium

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 7, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

September 1, 2025

Conditions
Pleomorphic Adenoma of the ParotidWarthin TumorHead and Neck DisorderHead and NeckThyroid DiseaseThyroidectomy
Interventions
DRUG

Fluorescein Sodium

Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg

Trial Locations (1)

94304

Stanford Medical Center, Palo Alto

All Listed Sponsors
collaborator

National Institute on Deafness and Other Communication Disorders (NIDCD)

NIH

lead

Stanford University

OTHER